Cooley advised ACELYRIN, and Davis Polk advised the joint book-running managers. ACELYRIN, INC. announced its upsized initial public offering of 34,500,000 shares of common stock at...
ACELYRIN’s $621 Million Initial Public Offering
Geron Corporation’s $198 Million Upsized Public Offering
Cooley advised Geron, while Latham & Watkins represented the underwriters in the offering. Geron Corporation (Nasdaq: GERN), a late-stage clinical biopharmaceutical company, has announced the pricing...
Amgen’s Acquisition of Horizon Therapeutics
Cooley LLP and Matheson LLP advised Horizon, while Sullivan & Cromwell LLP and William Fry LLP advised Amgen. Debevoise & Plimpton LLP advised JP Morgan. Macfarlanes...
Lyell Immunopharma’s $425 Million Initial Pubic Offering
Latham & Watkins Advises the Underwriters in the offering while Cooley LLP represented Lyell Immunopharma. Lyell Immunopharma, Inc. (Lyell), (Nasdaq: LYEL), a T cell reprogramming company...